2024-11-11
1. Summary of the week
In the first week of November, 17 licensing and cooperation deals were signed in total. In the China biotech industry, there were three out-licensing deals and seven domestic deals.
The week’s top out-licensing deal was between Leads Biolabs and Oblenio Bio, a NewCoco-established with Aditum Bio, for the tri-specific T-cell engager antibody LBL-051, valued at $614 million with an upfront payment of $35 million, and an equity stake in Oblenio Bio. It was a productive week domestically as well, with seven collaboration and licensing deals signed.
Globally, seven licensing and cooperation deals were signed. The top deal was SyndaxPharmaceuticals and Royalty Pharma entered into $350 million royalty funding agreement for the Phase II asset axatilimab.
2024年11月的头一周（1日-8日），全球医药市场共签署了17项资产授权和合作协议。中国市场共达成10项交易，包括3项出海交易和7项国内交易。
本周中国市场最引人注目的出海交易是维立志博授予Oblenio Bio公司，一家与Aditum Bio联合成立的NewCo，三特异性抗体LBL-051的独家选择和许可权，首付款3500万美元，总价值6.14亿美元，以及Oblenio Bio公司股权。本周国内交易迎来高峰，达成了7项合作和许可协议。
国际市场上，共签署了7项资产授权和合作协议。最大的一笔交易是SyndaxPharmaceuticals与Royalty Pharma就前者的临床二期资产Axatilimab达成的价值3.5亿美元的特许权使用费融资协议。
2. Licensing Deals
2a. China section
2b. Global section
3. M&A Deals
4. Top Deals of the year 2024
5. 2019-2023 China Innovative Drug Licensing Transactions
About YAFO Capital
Founded in 2013, YAFO Capital is a Shanghai based boutique investment and advisory firm, with professional team in our China, U.S., EU and SEA offices. Partnering with Pharmaceutical companies, YAFO Fund mainly invests in global assets. YAFO Life Sciences is a leading advisory boutique focused on asset transactions. YAFO has built a strong proven track record and closed dozens of in-licensing and out-licensing transactions with global pharma and biotech companies. Over the past five years, YAFO has been ranked as the No. 1 advisor for China cross border licensing transactions. For more information, please visit http://www.yafocapital.com
雅法资本成立于2013年，作为新型投资和投行咨询机构，致力于中国及海外生物医药项目的投融资、资产跨境交易和资产孵化等。旗下雅法基金联合药企进行资产投资和并购，雅法全球医疗专注于医药产品跨境及国内授权交易。基于雅法在全球广泛的人脉与资源网络，在过去十年成功推进了大量的海外项目进入中国市场并协助多个中国产品完成海外授权。雅法拥有经验丰富的全球交易团队，覆盖美国、日本 、欧洲等全球主要医药创新区域。核心合伙人均为华尔街资深投行人士或具有跨国药企经历，为客户交易提供强力支持。雅法总部位于上海，在美国、欧洲、东南亚等地均设有分部。雅法在生物医药跨境授权及并购业务交易数量连续多年排名第一。
ACCESS CHINA
Event Name:
2024-09 药通中国秋季路演，线上&云南
2024-09 ACCESS CHINA Autumn Roadshow, Virtual & Yunnan
2025-01 药通中国论坛@JPM，线上&旧金山
2025-01 ACCESS CHINA @ JPM Week, Virtual & San Francisco
BioToChina.org 